Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Vaccine Administration Payment Conundrum Addressed In Tax Bill

Executive Summary

Physician administration of Part D vaccines will be covered under Medicare Part B during 2007 and under Part D in 2008 and thereafter, under broad tax and health care legislation (HR 6111) signed into law by President George Bush Dec. 20

You may also be interested in...



COVID And Medicare: Pricing Restraints Needed For Part B Vaccines, MedPAC Panelists Say

GSK’s blockbuster Shingrix and other Part D vaccines would be switched to Part B under proposal being developed by influential advisory commission. Lack of pricing controls in Part B is generating concerns among panelists, though, as MedPAC aims to finalize its recommendations on revising Medicare reimbursement for vaccines by next spring.

Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track

Merck will seek to drive continued growth of its shingles vaccine Zostavax through promotional activity and efforts to facilitate reimbursement, the firm said

Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track

Merck will seek to drive continued growth of its shingles vaccine Zostavax through promotional activity and efforts to facilitate reimbursement, the firm said

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel